{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:48:17Z","timestamp":1787507297483,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ejphar.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T23:48:43Z","timestamp":1551484123000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["New insight into NANOG: A novel therapeutic target for ovarian cancer (OC)"],"prefix":"10.1016","volume":"852","author":[{"given":"Iyer","family":"Mahalaxmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam Mohana","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaramayya","family":"Kaavya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanasamy","family":"Arul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vellingiri","family":"Balachandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran Sivanandan","family":"Santhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.03.003_bib1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mam.2013.06.002","article-title":"Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets","volume":"39","author":"Ahmed","year":"2014","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.ejphar.2019.03.003_bib2","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/cc.25402","article-title":"In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals","volume":"12","author":"Badeaux","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejphar.2019.03.003_bib3","doi-asserted-by":"crossref","unstructured":"Baker, M., 2009. What does Nanog do? \u3008https:\/\/doi.org\/10.1038\/stemcells.2009.118\u3009.","DOI":"10.1038\/stemcells.2009.118"},{"key":"10.1016\/j.ejphar.2019.03.003_bib4","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib5","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3390\/ijms18112362","article-title":"ABC transporters in cancer stem cells: beyond chemoresistance","volume":"18","author":"Begicevic","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2019.03.003_bib6","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.03.003_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2005.08.020","article-title":"Core transcriptional regulatory circuitry in human embryonic stem cells","volume":"122","author":"Boyer","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(03)00392-1","article-title":"Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells","volume":"113","author":"Chambers","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib9","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1242\/dev.024398","article-title":"The transcriptional foundation of pluripotency","volume":"136","author":"Chambers","year":"2009","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2019.03.003_bib10","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1002\/jcp.24076","article-title":"Nanog regulates molecules involved in stemness and cell cycle-signaling pathway for maintenance of pluripotency of P19 embryonal carcinoma stem cells","volume":"227","author":"Choi","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1101\/gad.1642408","article-title":"Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells","volume":"22","author":"Cole","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2019.03.003_bib12","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1101\/gad.221176.113","article-title":"A genetic and developmental pathway from STAT3 to the OCT4\u2013NANOG circuit is essential for maintenance of ICM lineages in vivo","volume":"27","author":"Do","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejphar.2019.03.003_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.tips.2009.03.003","article-title":"Regulatory circuits underlying pluripotency and reprogramming","volume":"30","author":"Do","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.03.003_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-262","article-title":"Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention","volume":"13","author":"Ffrench","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2015.1121348","article-title":"The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells","volume":"17","author":"Gawlik-Rzemieniewska","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejphar.2019.03.003_bib16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature08592","article-title":"Direct cell reprogramming is a stochastic process amenable to acceleration","volume":"462","author":"Hanna","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbcan.2006.09.001","article-title":"Signalling via integrins: implications for cell survival and anticancer strategies","volume":"1775","author":"Hehlgans","year":"2007","journal-title":"Biochim. Biophys. Acta BBA - Rev. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.stem.2009.12.009","article-title":"The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells","volume":"6","author":"Heng","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib19","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1038\/527S217a","article-title":"Ovarian cancer: beyond resistance","volume":"527","author":"Holmes","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","article-title":"Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant","volume":"102","author":"Hu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib21","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/stem.2007","article-title":"Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions","volume":"33","author":"Jeter","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.ejphar.2019.03.003_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/scd.2009.0113","article-title":"Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs","volume":"18","author":"Kashyap","year":"2009","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.ejphar.2019.03.003_bib23","article-title":"Cancer stem cell\u2013related marker NANOG expression in ovarian serous tumors: a clinicopathological study of 159 cases","volume":"27","author":"Kenda \u0160uster","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib24","unstructured":"Kenda Suster, N., Virant-Klun, I., Grazio, S., Smrkolj, S., 2016. The significance of the pluripotency and cancer stem cell-related marker NANOG in diagnosis and treatment of ovarian carcinoma. \u3008https:\/\/doi.org\/10.12892\/ejgo3121.2016\u3009."},{"key":"10.1016\/j.ejphar.2019.03.003_bib25","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.3390\/ijms14046624","article-title":"Regulation of ovarian cancer stem cells or tumor-initiating cells","volume":"14","author":"Kwon","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2019.03.003_bib26","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1242\/dev.006569","article-title":"The Oct4 homologue PouV and Nanog regulate pluripotency in chicken embryonic stem cells","volume":"134","author":"Lavial","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2019.03.003_bib27","first-page":"22","article-title":"Prognostic impact of the cancer stem cell\u2013related marker NANOG in ovarian serous carcinoma","author":"Lee","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib29","first-page":"29","article-title":"Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism","author":"Li","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13048-018-0403-2","article-title":"Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR\/Cas9 system","volume":"11","author":"Ling","year":"2018","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib31","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.1007\/s13277-016-4848-x","article-title":"NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer","volume":"37","author":"Liu","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib32","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/onc.2013.209","article-title":"The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis","volume":"33","author":"Lu","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2019.03.003_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.stem.2007.05.014","article-title":"Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution","volume":"1","author":"Maherali","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib34","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1002\/jcb.26753","article-title":"Stemness and chemoresistance are imparted to the OC cells through TGF\u03b21 driven EMT","volume":"119","author":"Mitra","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2019.03.003_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0092-8674(03)00393-3","article-title":"The homeoprotein nanog is required for maintenance of pluripotency in mouse epiblast and ES cells","volume":"113","author":"Mitsui","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib36","first-page":"127","article-title":"Survival and apoptotic signals in the action of microtubule-targeting antitumor drugs","volume":"8","author":"Mollinedo","year":"2005","journal-title":"IDrugs Investig. Drugs J."},{"key":"10.1016\/j.ejphar.2019.03.003_bib37","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.bbrc.2012.12.149","article-title":"Reprogramming of mouse fibroblasts into induced pluripotent stem cells with Nanog","volume":"431","author":"Moon","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2019.03.003_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.018","article-title":"Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells \u2013 an updated review","volume":"362","author":"Muinao","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib39","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1172\/JCI64057","article-title":"Nanog signaling in cancer promotes stem-like phenotype and immune evasion","volume":"122","author":"Noh","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2019.03.003_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","article-title":"Generation of germline-competent induced pluripotent stem cells","volume":"448","author":"Okita","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib41","first-page":"67","article-title":"Ovarian cancer stem cells more questions than answers","volume":"44","author":"Ottevanger","year":"2017","journal-title":"Prog. Biol. Underst. Cancer Metastasis"},{"key":"10.1016\/j.ejphar.2019.03.003_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000320866","article-title":"Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade","volume":"77","author":"Pan","year":"2010","journal-title":"Pathobiology"},{"key":"10.1016\/j.ejphar.2019.03.003_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40104-018-0260-2","article-title":"Molecular characterization and expression patterns of Nanog gene validating its involvement in the embryonic development and maintenance of spermatogonial stem cells of farmed carp, Labeo rohita","volume":"9","author":"Patra","year":"2018","journal-title":"J. Anim. Sci. Biotechnol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/1757-2215-1-4","article-title":"Ovarian cancer: emerging concept on cancer stem cells","volume":"1","author":"Ponnusamy","year":"2008","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib46","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160247","article-title":"NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer","volume":"37","author":"Qin","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejphar.2019.03.003_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/onc.2016.320","article-title":"Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance","volume":"36","author":"Ramadoss","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2019.03.003_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1757-2215-5-37","article-title":"Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary","volume":"5","author":"Samardzija","year":"2012","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib49","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/ijc.28690","article-title":"Emerging role of Nanog in tumorigenesis and cancer stem cells","volume":"135","author":"Santaliz-Ruiz","year":"2014","journal-title":"Int. J. Cancer J. Int. Cancer"},{"key":"10.1016\/j.ejphar.2019.03.003_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/07357900801904140","article-title":"Expression of multidrug resistance genes in normal and cancer stem cells","volume":"26","author":"Shervington","year":"2008","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ejphar.2019.03.003_bib51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2009.07.039","article-title":"Nanog Is the gateway to the pluripotent ground state","volume":"138","author":"Silva","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib52","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1634\/stemcells.2007-0126","article-title":"A heterogeneous expression pattern for Nanog in embryonic stem cells","volume":"25","author":"Singh","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.ejphar.2019.03.003_bib53","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1038\/onc.2012.363","article-title":"Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers","volume":"32","author":"Siu","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2019.03.003_bib54","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-11-2188","article-title":"Stem cell pathways contribute to clinical chemoresistance in ovarian cancer","volume":"18","author":"Steg","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2019.03.003_bib55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib56","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1242\/dev.068775","article-title":"Reprogramming capacity of Nanog is functionally conserved in vertebrates and resides in a unique homeodomain","volume":"138","author":"Theunissen","year":"2011","journal-title":"Development"},{"key":"10.1016\/j.ejphar.2019.03.003_bib57","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.molcel.2013.10.003","article-title":"High Dub3 expression in Mouse ESCs couples the G1\/S checkpoint to pluripotency","volume":"52","author":"van der Laan","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejphar.2019.03.003_bib58","doi-asserted-by":"crossref","first-page":"e93663","DOI":"10.1371\/journal.pone.0093663","article-title":"Cell cycle-dependent expression of Dub3, Nanog and the p160 family of Nuclear Receptor Coactivators (NCoAs) in Mouse embryonic stem cells","volume":"9","author":"van der Laan","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejphar.2019.03.003_bib59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nature09781","article-title":"Cells of origin in cancer","volume":"469","author":"Visvader","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4252\/wjsc.v6.i4.441","article-title":"Ovarian cancer stem cells: can targeted therapy lead to improved progression-free survival?","volume":"6","author":"Walters Haygood","year":"2014","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.ejphar.2019.03.003_bib61","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature05284","article-title":"A protein interaction network for pluripotency of embryonic stem cells","volume":"444","author":"Wang","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib62","doi-asserted-by":"crossref","first-page":"44191","DOI":"10.18632\/oncotarget.6176","article-title":"Cancer stem cell targeted therapy: progress amid controversies","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2019.03.003_bib63","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature05944","article-title":"In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state","volume":"448","author":"Wernig","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.03.003_bib64","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.bbrc.2018.07.118","article-title":"Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells","volume":"503","author":"Woo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2019.03.003_bib65","series-title":"Immune Evasion by Nanog-Mediated Changes to the Tumor Microenvironment","author":"Wu","year":"2014"},{"key":"10.1016\/j.ejphar.2019.03.003_bib66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/onc.2013.537","article-title":"Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer","volume":"34","author":"Xiang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2019.03.003_bib67","doi-asserted-by":"crossref","first-page":"34970","DOI":"10.1074\/jbc.M112.374611","article-title":"MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53\/Nanog","volume":"287","author":"Xu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.03.003_bib68","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.modgep.2005.03.001","article-title":"Nanog expression in mouse germ cell development","volume":"5","author":"Yamaguchi","year":"2005","journal-title":"Gene Expr. Patterns"},{"key":"10.1016\/j.ejphar.2019.03.003_bib69","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2019.03.003_bib70","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejphar.2019.03.003_bib71","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1083\/jcb.200801009","article-title":"A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A.","volume":"184","author":"Zhang","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2019.03.003_bib72","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ijc.28774","article-title":"miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6","volume":"135","author":"Zhu","year":"2014","journal-title":"Int. J. Cancer"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:26:22Z","timestamp":1757975182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":72,"alternative-id":["S0014299919301529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.03.003","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insight into NANOG: A novel therapeutic target for ovarian cancer (OC)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}